Search

Your search keyword '"Orsi, G."' showing total 1,080 results
Start Over Author "Orsi, G."
1,080 results on '"Orsi, G."'

1. Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey

Author

Reni, M., Giommoni, E., Bergamo, F., Cavanna, L., Simionato, F., Spada, M., Di Marco, M., Bernardini, I., Cordio, S.S., Latiano, T., Spallanzani, A., Silvestris, N., Cardellino, G.G., Bonomi, M., Milella, M., Luchena, G., Tamburini, E., Macchini, M., Orsi, G., Modesti, M., Procaccio, L., Santoni, A., De Simone, I., Caldirola, L., Galli, F., and Pinto, C.

Published
2024
Full Text
View/download PDF

2. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

3. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

Author

Orsi, G., Di Marco, M., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I.G., Garajova, I., Tortora, G., Rodriquenz, M.G., Bittoni, A., Penzo, E., De Lorenzo, S., Peretti, U., Paratore, C., Bernardini, I., Mosconi, S., Spallanzani, A., Macchini, M., Tamburini, E., Bencardino, K., Giommoni, E., Scartozzi, M., Forti, L., Valente, M.M., Militello, A.M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

4. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Author

Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M.C., Rodriquenz, M.G., Centonze, F., Rapposelli, I.G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L.G., Orsi, G., Valente, M.M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

5. Epileptologists telling their experiences caring for patients with epilepsy

Author

Aguglia, U., Assenza, G., Audenino, D., Benna, P., Bilo, L., Boero, G., Costa, C., D’Orsi, G., De Liso, A., De Palma, L., Elia, M., Ferrari, A., La Neve, A., Lalla, A., Michelucci, R., Minicucci, F., Mostacci, B., Piazza, F., Quarato, PP, Ranzato, F., Tassi, L., Vatti, G., Vignoli, A., Chesi, P., Marini, M.G., Scarlata, P., and Mecarelli, O.

Published
2021
Full Text
View/download PDF

6. First-aid management of tonic-clonic seizures among healthcare personnel: A survey by the Apulian section of the Italian League Against Epilepsy

Author

d'Orsi, G., Martino, T., Lalla, A., Carapelle, E., Di Claudio, M.T., Avolio, C., Pustorino, G., Polito, A.N., La Neve, A., Francavilla, T., Boero, G., Pontrelli, G., Internò, S., Patanè, S., Germano, M., La Selva, L., Sciruicchio, V., Durante, V., Scarpello, R., Elia, M., Martino, Tommaso, Lalla, Alessandra, Carapelle, Elena, Di Claudio, Maria Teresa, Avolio, Carlo, and d'Orsi, Giuseppe

Published
2018
Full Text
View/download PDF

7. Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Author

Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Trama A., Vener C., Lasalvia P., Bernasconi A., Zorzi M., Andreano A., Contiero P., Manneschi G., Falcini F., Castaing M., Filiberti R. A., Gasparotti C., Cirilli C., Amodio R., Bisceglia I., Iacovacci S., Vitale M. F., Stracci F., Gentilini M. A., Tumino R., Carone S., Sampietro G., Melcarne A., Gatti L., Boschetti L., Corti M., Rognoni M., Coviello E., Pesce M. T., D'Orsi G., Fanetti A. C., De Lorenzis L., Candela G., Savoia F., Pascucci C., Castelli M., Storchi C., Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Trama A., Vener C., Lasalvia P., Bernasconi A., Zorzi M., Andreano A., Contiero P., Manneschi G., Falcini F., Castaing M., Filiberti R. A., Gasparotti C., Cirilli C., Amodio R., Bisceglia I., Iacovacci S., Vitale M. F., Stracci F., Gentilini M. A., Tumino R., Carone S., Sampietro G., Melcarne A., Gatti L., Boschetti L., Corti M., Rognoni M., Coviello E., Pesce M. T., D'Orsi G., Fanetti A. C., De Lorenzis L., Candela G., Savoia F., Pascucci C., Castelli M., and Storchi C.

Abstract

Background: Increased success in the treatment of hematological cancers contributed to the increase of 5-year survival for most adolescent and young adults (AYAs) with these tumours. However, as 5-year survival increased, it became clear that AYA long-term survivors were at increased risk for severe late effects. Moreover, limited information on long-term cancer impact is available for AYAs, since most studies focused on children and adolescents. We aimed to assess various long-term outcomes on AYA survivors of hematological cancers. Methods: We selected patients diagnosed with a first primary hematological cancer between 1997 and 2006, in the Italian nationwide population-based cohort of AYA cancer survivors (i.e. alive at least 5 years after cancer diagnosis). Long-term outcomes of interest were: second malignant neoplasms (SMNs), hospitalizations and overall mortality. We calculated standardized incidence ratios (SIRs), standardized hospitalization rate ratios (SHRs) and standardized mortality rate ratios (SMRs). To study morbidity patterns over time, we modeled observed incidence rates by fitting flexible parametric models for nonlinear patterns and we used linear regression for linear patterns. Results: The study cohort included 5,042 AYA hematological cancer survivors of which 1,237 and 3,805 had a leukaemia and lymphoma diagnosis, respectively. AYA survivors were at substantially increased risk for SMN (SIR=2.1; 95%CI=1.7; 2.6), hospitalisation (SHR=1.5; 95%CI=1.5; 1.6), and mortality (SMR=1.4; 95%CI=1.2; 1.6) with differences between leukaemia and lymphoma survivors. The highest excess risks of hospitalisations were for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity pattern differs over time by morbidity type. Conclusions: Our results support the need for strict follow-up plans for survivors, and call for further study to better personalised follow-up plans for AYA cancer survivors.

Published
2022

11. Elderly patients with multimorbidity in the home setting: umbrella review on therapeutic non-adherence causes.

Author

LIQUORI, G., DIONISI, S., GIANNETTA, N., DI SIMONE, E., DE LEO, A., PANATTONI, N., RICCIARDI, F., GRIECO, A., ORSI, G. B., and DI MUZIO, M.

Abstract

OBJECTIVE: The elderly population is the most at risk regarding adherence, especially in the coexistence of multiple diseases. This study aims to detect factors contributing to therapeutic non-adherence in elderly patients in home settings. MATERIALS AND METHODS: A review protocol was developed to conduct the umbrella review using the methodological framework of the Richardson et al study. The search strategy was developed in December 2022 to conduct a systematic search and to perform an Umbrella Review of systematic reviews, meta-analyses and integrative reviews published from 2012 to 2022 in English. RESULTS: A total of 26,038 articles were identified and screened. 18 relevant articles were included in the study. CONCLUSIONS: Therapeutic adherence in elderly patients with comorbidities in polypharmacotherapy at home is a significant problem in public health and health care. Several factors of non-adherence have been identified in the studies reviewed, confirming that the problem is multifactorial. Reducing the number of medications prescribed would appear optimal, although often not possible, as this has been seen to have an immediate positive impact. A multidisciplinary approach makes it possible not to fragment care, ensuring positive feedback on therapeutic adherence. [ABSTRACT FROM AUTHOR]

Published
2023

16. Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Author

Trama, A., Vener, C., Lasalvia, P., Bernasconi, A., Zorzi, M., Andreano, A., Contiero, P., Manneschi, G., Falcini, F., Castaing, M., Filiberti, R. A., Gasparotti, C., Cirilli, C., Amodio, R., Bisceglia, I., Iacovacci, S., Vitale, M. F., Stracci, F., Gentilini, M. A., Tumino, R., Carone, S., Sampietro, G., Melcarne, A., Gatti, L., Boschetti, L., Corti, M., Rognoni, M., Coviello, E., Pesce, M. T., D'Orsi, G., Fanetti, A. C., De Lorenzis, L., Candela, G., Savoia, F., Pascucci, C., Castelli, M., Storchi, C., Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, and Storchi, C

Subjects
adolescents and young adults (AYAs), long-term outcome, Cancer Research, Oncology, cancer survivor, hematological cancers, cancer survivors, hematological cancer, population-based cohort, long-term outcomes
Abstract

BackgroundIncreased success in the treatment of hematological cancers contributed to the increase of 5-year survival for most adolescent and young adults (AYAs) with these tumours. However, as 5-year survival increased, it became clear that AYA long-term survivors were at increased risk for severe late effects. Moreover, limited information on long-term cancer impact is available for AYAs, since most studies focused on children and adolescents. We aimed to assess various long-term outcomes on AYA survivors of hematological cancers.MethodsWe selected patients diagnosed with a first primary hematological cancer between 1997 and 2006, in the Italian nationwide population-based cohort of AYA cancer survivors (i.e. alive at least 5 years after cancer diagnosis). Long-term outcomes of interest were: second malignant neoplasms (SMNs), hospitalizations and overall mortality. We calculated standardized incidence ratios (SIRs), standardized hospitalization rate ratios (SHRs) and standardized mortality rate ratios (SMRs). To study morbidity patterns over time, we modeled observed incidence rates by fitting flexible parametric models for nonlinear patterns and we used linear regression for linear patterns.ResultsThe study cohort included 5,042 AYA hematological cancer survivors of which 1,237 and 3,805 had a leukaemia and lymphoma diagnosis, respectively. AYA survivors were at substantially increased risk for SMN (SIR=2.1; 95%CI=1.7; 2.6), hospitalisation (SHR=1.5; 95%CI=1.5; 1.6), and mortality (SMR=1.4; 95%CI=1.2; 1.6) with differences between leukaemia and lymphoma survivors. The highest excess risks of hospitalisations were for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity pattern differs over time by morbidity type.ConclusionsOur results support the need for strict follow-up plans for survivors, and call for further study to better personalised follow-up plans for AYA cancer survivors.

Published
2022

17. Volcanic Hazard Assessment at the Campi Flegrei Caldera, Italy

Author

Bevilacqua A., Macedonio G., Neri A., Orsi G., Petrosino P., Lucia Civetta, Massimo D'Antonio, Giovanni Orsi, Bevilacqua, A., Macedonio, G., Neri, A., Orsi, G., and Petrosino, P.

Abstract

The Campi Flegrei caldera is a complex and resurgent structure, and its active portion has been the site of an intense volcanism with eruptions concentrated in temporal clusters, called epochs. The caldera is home to about 350,000 people. In the past decades, many scientific studies were aimed at both defining fundamental parameters of a future eruption, and hazard zoning of the territory. The approach to the volcanic hazard assessment of the Campi Flegrei caldera has progressively changed through time from a “deterministic” interpretation of the available information to a quantitative probabilistic elaboration of the main sources of uncertainty. In particular, on the long-term, Astroni-Agnano-Solfatara is recognised to be the most probable area in which a vent will likely open, while the Averno-Monte Nuovo is the second most probable one. Significant uncertainty affects these results, and a non-negligible vent opening probability spreads over the whole caldera. The inter-event times of volcanic eruptions span from a few years to thousands of years. Within the epochs of activity, the mean recurrence time is tens of years, and intra-epoch temporal groups are evident. The probability that the next eruption will be of < 0.1 km3 volume of magma DRE is ~95%. Larger size eruptions tend to be localised in the central-eastern sector of the caldera. Expected hazards from renewal of explosive volcanism result from pyroclastic fallout and pyroclastic density currents. Pyroclastic fallout deposits in excess of 300 kg/m2 can affect most of the caldera and the city of Naples with more than 10% probability. The entire caldera has the potential to be affected by pyroclastic density currents invasion with mean probability above 30% in its central-eastern portion, and above 50% in the Agnano area. Invasion probabilities of ~5–10% have been estimated for the urbanised areas along the eastern slopes of the Posillipo Hill. In summary, probabilistic hazard assessment is particularly important in Campi Flegrei caldera, due to the uncertain location for potential vents and the large variability of eruption styles and sizes that cannot be, at the present time, effectively constrained by monitoring signals.

Published
2022
Full Text
View/download PDF

18. Intravenous brivaracetam in status epilepticus: A multicentric retrospective study in Italy

Author

Orlandi, N, Bartolini, E, Audenino, D, Moja, M, Urso, L, D'Orsi, G, Pauletto, G, Nilo, A, Zinno, L, Cappellani, R, Zummo, L, Giordano, A, Dainese, F, Nazerian, P, Pescini, F, Beretta, S, Dono, F, Gaudio, L, Ferlisi, M, Marino, D, Piccioli, M, Renna, R, Rosati, E, Rum, A, Strigaro, G, Giovannini, G, Meletti, S, Cavalli, S, Contento, M, Cottone, S, Di Claudio, M, Florindo, I, Guadagni, M, Kiferle, L, Lazzaretti, D, Lazzari, M, Coco, D, Pradella, S, Rikani, K, Rodorigo, D, Sabetta, A, Sicurella, L, Tontini, V, Turchi, G, Vaudano, A, Zanoni, T, Orlandi N., Bartolini E., Audenino D., Moja M. C., Urso L., d'Orsi G., Pauletto G., Nilo A., Zinno L., Cappellani R., Zummo L., Giordano A., Dainese F., Nazerian P., Pescini F., Beretta S., Dono F., Gaudio L. D., Ferlisi M., Marino D., Piccioli M., Renna R., Rosati E., Rum A., Strigaro G., Giovannini G., Meletti S., Cavalli S. M., Contento M., Cottone S., Di Claudio M. T., Florindo I., Guadagni M., Kiferle L., Lazzaretti D., Lazzari M., Coco D. L., Pradella S., Rikani K., Rodorigo D., Sabetta A., Sicurella L., Tontini V., Turchi G., Vaudano A. E., Zanoni T., Orlandi, N, Bartolini, E, Audenino, D, Moja, M, Urso, L, D'Orsi, G, Pauletto, G, Nilo, A, Zinno, L, Cappellani, R, Zummo, L, Giordano, A, Dainese, F, Nazerian, P, Pescini, F, Beretta, S, Dono, F, Gaudio, L, Ferlisi, M, Marino, D, Piccioli, M, Renna, R, Rosati, E, Rum, A, Strigaro, G, Giovannini, G, Meletti, S, Cavalli, S, Contento, M, Cottone, S, Di Claudio, M, Florindo, I, Guadagni, M, Kiferle, L, Lazzaretti, D, Lazzari, M, Coco, D, Pradella, S, Rikani, K, Rodorigo, D, Sabetta, A, Sicurella, L, Tontini, V, Turchi, G, Vaudano, A, Zanoni, T, Orlandi N., Bartolini E., Audenino D., Moja M. C., Urso L., d'Orsi G., Pauletto G., Nilo A., Zinno L., Cappellani R., Zummo L., Giordano A., Dainese F., Nazerian P., Pescini F., Beretta S., Dono F., Gaudio L. D., Ferlisi M., Marino D., Piccioli M., Renna R., Rosati E., Rum A., Strigaro G., Giovannini G., Meletti S., Cavalli S. M., Contento M., Cottone S., Di Claudio M. T., Florindo I., Guadagni M., Kiferle L., Lazzaretti D., Lazzari M., Coco D. L., Pradella S., Rikani K., Rodorigo D., Sabetta A., Sicurella L., Tontini V., Turchi G., Vaudano A. E., and Zanoni T.

Abstract

Purpose: to evaluate the use, effectiveness, and adverse events of intravenous brivaracetam (BRV) in status epilepticus (SE). Methods: a retrospective multicentric study involving 24 Italian neurology units was performed from March 2018 to June 2020. A shared case report form was used across participating centres to limit biases of retrospective data collection. Diagnosis and classification of SE followed the 2015 ILAE proposal. We considered a trial with BRV a success when it was the last administered drug prior the clinical and/or EEG resolution of seizures, and the SE did not recur during hospital observation. In addition, we considered cases with early response, defined as SE resolved within 6 h after BRV administration. Results: 56 patients were included (mean age 62 years; 57 % male). A previous diagnosis of epilepsy was present in 21 (38 %). Regarding SE etiology classification 46 % were acute symptomatic, 18 % remote and 16 % progressive symptomatic. SE episodes with prominent motor features were the majority (80 %). BRV was administered as first drug after benzodiazepine failure in 21 % episodes, while it was used as the second or the third (or more) drug in the 38 % and 38 % of episodes respectively. The median loading dose was 100 mg (range 50−300 mg). BRV was effective in 32 cases (57 %). An early response was documented in 22 patients (39 % of the whole sample). The use of the BRV within 6 h from SE onset was independently associated to an early SE resolution (OR 32; 95 % CI 3.39–202; p = 0.002). No severe treatment emergent adverse events were observed. Conclusion: BRV proved to be useful and safe for the treatment of SE. Time to seizures resolution appears shorter when it is administered in the early phases of SE.

Published
2021

19. The management of epilepsy in clinical practice: Do the timing and severity of the disease influence the priorities of patients and the caring physicians? Data from the EPINEEDS study

Author

Enia, G, Giussani, G, Bianchi, E, Mecarelli, O, Beghi, E, Pulitano, P, Cagnetti, C, Baldinelli, S, Lattanzi, S, La, N, Tappata, M, Francavilla, T, De Maria, G, Sofia, V, Giuliano, L, Mainieri, G, Fatuzzo, D, Belcastro, V, Elia, M, D'Orsi, G, Lalla, A, Salmaggi, A, Brigo, F, Magaudda, A, Pisani, F, Pisani, L, Raffaele, M, Cosenza, D, Villani, F, Quintas, R, Cervellione, R, Borroni, S, Meletti, S, Ferrarese, C, Barbella, G, Di Francesco, J, Bogliun, G, Beretta, S, Galimberti, C, Cantisani, T, Cecconi, M, Celani, M, Papetti, R, Giorgi, F, Aguglia, U, Gasparini, S, Ferlazzo, E, Manganotti, P, Crichiutti, G, Bravar, G, Enia G., Giussani G., Bianchi E., Mecarelli O., Beghi E., Pulitano P., Cagnetti C., Baldinelli S., Lattanzi S., La N. A., Tappata M., Francavilla T., De Maria G., Sofia V., Giuliano L., Mainieri G., Fatuzzo D., Belcastro V., Elia M., D'Orsi G., Lalla A., Salmaggi A., Brigo F., Magaudda A., Pisani F. G. S., Pisani L. R., Raffaele M., Cosenza D., Villani F. S., Quintas R. M. M., Cervellione R., Borroni S., Meletti S., Ferrarese C., Barbella G., Di Francesco J., Bogliun G., Beretta S., Galimberti C. A., Cantisani T. A., Cecconi M., Celani M. G., Papetti R., Giorgi F. S., Aguglia U., Gasparini S., Ferlazzo E., Manganotti P., Crichiutti G., Bravar G., Enia, G, Giussani, G, Bianchi, E, Mecarelli, O, Beghi, E, Pulitano, P, Cagnetti, C, Baldinelli, S, Lattanzi, S, La, N, Tappata, M, Francavilla, T, De Maria, G, Sofia, V, Giuliano, L, Mainieri, G, Fatuzzo, D, Belcastro, V, Elia, M, D'Orsi, G, Lalla, A, Salmaggi, A, Brigo, F, Magaudda, A, Pisani, F, Pisani, L, Raffaele, M, Cosenza, D, Villani, F, Quintas, R, Cervellione, R, Borroni, S, Meletti, S, Ferrarese, C, Barbella, G, Di Francesco, J, Bogliun, G, Beretta, S, Galimberti, C, Cantisani, T, Cecconi, M, Celani, M, Papetti, R, Giorgi, F, Aguglia, U, Gasparini, S, Ferlazzo, E, Manganotti, P, Crichiutti, G, Bravar, G, Enia G., Giussani G., Bianchi E., Mecarelli O., Beghi E., Pulitano P., Cagnetti C., Baldinelli S., Lattanzi S., La N. A., Tappata M., Francavilla T., De Maria G., Sofia V., Giuliano L., Mainieri G., Fatuzzo D., Belcastro V., Elia M., D'Orsi G., Lalla A., Salmaggi A., Brigo F., Magaudda A., Pisani F. G. S., Pisani L. R., Raffaele M., Cosenza D., Villani F. S., Quintas R. M. M., Cervellione R., Borroni S., Meletti S., Ferrarese C., Barbella G., Di Francesco J., Bogliun G., Beretta S., Galimberti C. A., Cantisani T. A., Cecconi M., Celani M. G., Papetti R., Giorgi F. S., Aguglia U., Gasparini S., Ferlazzo E., Manganotti P., Crichiutti G., and Bravar G.

Abstract

Objective: The objective of this study was to assess the priorities of patients with epilepsy and their caring physicians with reference to the timing and severity of the disease. Methods: This is a national survey in which patients with epilepsy followed in 21 Italian epilepsy centers, and their caring physicians were asked to fill anonymous questionnaires to collect data on different aspects of the disease and their needs and priorities in its management. The collected information included demographics, clinical profile and diagnosis, treatment and outcome of epilepsy. The questions were designed to understand the expectations of the patients and their caring physicians and verify the degree of concordance between patient and doctor. The study population was divided in six prognostic categories: (1) Newly diagnosed epilepsy; (2) Absence of seizures for at least 2 years; (3) Absence of seizures for at least 1 year or occasional seizures; (4) Nondrug-resistant recurrent seizures; (5) drug-resistant seizures; (6) surgical candidate. Results: Of the 787 patients enrolled, 432 were women and 355 men aged 15 to 88 years (median 41 years). Disease duration ranged from 6 months to 75 years. The sample included 53 patients with newly diagnosed epilepsy, 283 without seizures for at least 2 years, 162 seizure-free for at least 1 year or with occasional seizures, 123 with nondrug-resistant recurrent seizures, 128 with drug-resistant seizures, and 38 surgical candidates. Significant differences were found between patients and physicians in terms of priorities and needs with reference to the management of the disease. While physicians tend to prioritize the information on the diagnosis and treatment of epilepsy depending on timing and severity, patients focus on the search of the cause, the side effects of drugs, and the effects of any new treatment on the control of seizures regardless of the prognostic category. In addition, physicians tend to undervalue the communication of

Published
2021

20. Ensuring safety requirement to home food and home restaurant: focus on a regional experience based on sector legislation, and future perspectives.

Author

Marzocca, P., Daleno, D., Orsi, G. B., Napoli, C., and Marcotrigiano, V.

Subjects
RESTAURANTS, SHARING economy, BUSINESS development, FOOD safety, PUBLIC health
Abstract

The sharing economy provides many new business opportunities, particularly in local areas where culinary traditions guarantee major appreciable sensorial features. In this context, home food and home restaurant find their place. The first one refers to businesses that, in a home kitchen or in premises used mainly as a private home, produce food for retail, while the second one is defined as food businesses producing and administering food and beverages in a private dwelling house. This manuscript analyses the sector legislation applicable to these new business forms, the adherence to the requirements prescribed by the recent guidelines, the executive compliance applicable to the inspection phases, as well as the perspectives and future challenges that healthcare workers designated for food safety official controls will face. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients

Author

Macchini M., Centonze F., Peretti U., Orsi G., Militello A. M., Valente M. M., Cascinu S., Reni M., Macchini, M., Centonze, F., Peretti, U., Orsi, G., Militello, A. M., Valente, M. M., Cascinu, S., and Reni, M.

Subjects
BRCA2 Protein, Epidemiology, BRCA1 Protein, Pharmaco-ethnicity, General Medicine, Prognosis, BRCA1-2 pathogenic variants, Pancreatic Neoplasms, Oncology, Familiar pancreatic cancer, DNA Damage Response pathogenic variants, Humans, Radiology, Nuclear Medicine and imaging, Pancreatic adenocarcinoma, Germ-Line Mutation, Carcinoma, Pancreatic Ductal, DNA Damage
Abstract

Incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing over the last years, while patients prognosis remains grim. Recently germline BRCA1 and 2 pathogenic variants (gBRCA1-2) have emerged as risk factors for PDAC development, as well as new predictors of response to specific therapeutic interventions. However, data on gBRCA1-2 incidence in PDAC are currently sparse and limited to selected categories of patients, as for positive cancer history cases, for patients affected only by early or late stages of disease and mainly from the North-American population, thus generating incomplete information about the gBRCA1/2 epidemiology. In Western Countries gBRCA1-2 incidence ranges between 4.5% and 8% in unselected PDAC patients, raising up to 26% in cohorts with positive family cancer history. To date a limited number of studies from Asian countries are available, reporting a 10% as highest incidence of gBRCA1-2 in familiar PDAC, claiming at least in part a role of ethnicity in the gBRCA1-2 incidence and in other genes potentially implicated in the therapeutic decisions. Drawing a better defined map for the incidence of gBRCA1-2 and other germline pathogenic variants of DNA Damage Response genes (gDDR) might help assessing the therapeutic strategies for mutated patients according to the geographic areas. These informations may enhance the chance to predict efficacy and toxicity of selected chemotherapy regimens, fostering the development and implementation of the pharmaco-ethnicity knowledge in the routine-clinical practice, and increasing the awareness of the potential incorrect generalization of trials results outside of the geographic area where they are conducted.

Published
2021

23. 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations

Author

Milella, M., primary, Orsi, G., additional, Palloni, A., additional, Salvatore, L., additional, Procaccio, L., additional, Noventa, S., additional, Bozzarelli, S., additional, Garajova, I., additional, Vasile, E., additional, Giordano, G., additional, Macchini, M., additional, Cavaliere, A., additional, Gaule, M., additional, Lonardi, S., additional, Di Marco, M.C., additional, Tortora, G., additional, Sperduti, I., additional, and Reni, M., additional

Published
2022
Full Text
View/download PDF

25. The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study

Author

Giussani, G, Enia, G, Bianchi, E, Mecarelli, O, Beghi, E, Pulitano, P, Cagnetti, C, Baldinelli, S, La Neve, A, Tappata, M, Francavilla, T, De Maria, G, Sofia, V, Giuliano, L, Mainieri, G, Fatuzzo, D, Belcastro, V, Elia, M, D'Orsi, G, Lalla, A, Salmaggi, A, Brigo, F, Magaudda, A, Pisani, F, Galletta, S, Pisani, L, Raffaele, M, Cosenza, D, Villani, F, Quintas, R, Cervellione, R, Borroni, S, Meletti, S, Ferrarese, C, Barbella, G, Di Francesco, J, Bogliun, G, Beretta, S, Galimberti, C, Cantisani, T, Cecconi, M, Celani, M, Papetti, R, Giorgi, F, Aguglia, U, Gasparini, S, Ferlazzo, E, Manganotti, P, Crichiutti, G, Bravar, G, Giussani G., Enia G., Bianchi E., Mecarelli O., Beghi E., Pulitano P., Cagnetti C., Baldinelli S., La Neve A., Tappata M., Francavilla T., De Maria G., Sofia V., Giuliano L., Mainieri G., Fatuzzo D., Belcastro V., Elia M., D'Orsi G., Lalla A., Salmaggi A., Brigo F., Magaudda A., Pisani F., Galletta S., Pisani L. R., Raffaele M., Cosenza D., Villani F. S., Quintas R. M. M., Cervellione R., Borroni S., Meletti S., Ferrarese C., Barbella G., Di Francesco J., Bogliun G., Beretta S., Galimberti C. A., Cantisani T. A., Cecconi M., Celani M. G., Papetti R., Giorgi F. S., Aguglia U., Gasparini S., Ferlazzo E., Manganotti P., Crichiutti G., Bravar G., Giussani, G, Enia, G, Bianchi, E, Mecarelli, O, Beghi, E, Pulitano, P, Cagnetti, C, Baldinelli, S, La Neve, A, Tappata, M, Francavilla, T, De Maria, G, Sofia, V, Giuliano, L, Mainieri, G, Fatuzzo, D, Belcastro, V, Elia, M, D'Orsi, G, Lalla, A, Salmaggi, A, Brigo, F, Magaudda, A, Pisani, F, Galletta, S, Pisani, L, Raffaele, M, Cosenza, D, Villani, F, Quintas, R, Cervellione, R, Borroni, S, Meletti, S, Ferrarese, C, Barbella, G, Di Francesco, J, Bogliun, G, Beretta, S, Galimberti, C, Cantisani, T, Cecconi, M, Celani, M, Papetti, R, Giorgi, F, Aguglia, U, Gasparini, S, Ferlazzo, E, Manganotti, P, Crichiutti, G, Bravar, G, Giussani G., Enia G., Bianchi E., Mecarelli O., Beghi E., Pulitano P., Cagnetti C., Baldinelli S., La Neve A., Tappata M., Francavilla T., De Maria G., Sofia V., Giuliano L., Mainieri G., Fatuzzo D., Belcastro V., Elia M., D'Orsi G., Lalla A., Salmaggi A., Brigo F., Magaudda A., Pisani F., Galletta S., Pisani L. R., Raffaele M., Cosenza D., Villani F. S., Quintas R. M. M., Cervellione R., Borroni S., Meletti S., Ferrarese C., Barbella G., Di Francesco J., Bogliun G., Beretta S., Galimberti C. A., Cantisani T. A., Cecconi M., Celani M. G., Papetti R., Giorgi F. S., Aguglia U., Gasparini S., Ferlazzo E., Manganotti P., Crichiutti G., and Bravar G.

Abstract

Purpose: The purpose of this study was to assess the priorities of patients with epilepsy and caring physicians and the correspondence between these priorities. Methods: In this multicenter cross-sectional study, patients with epilepsy attending 21 Italian epilepsy centers and their caring physicians filled anonymously questionnaires on the needs and priorities in the management of the disease. Included were questions on patients' demographics, diagnosis, treatment, and outcome of epilepsy. The concordance between patients and their physicians was assessed on various aspects of the diagnosis and care of the disease. Patients' satisfaction with communication, services, and patient–doctor relationship was also assessed. Results: Included were 432 women and 355 men aged 15 to 88 years (median: 41 years). Disease duration ranged from 6 months to 75 years. A structural/metabolic etiology predominated (52.7%), followed by a (presumed) genetic etiology (33.0%). Seizure remission was present in 56.5% of cases. Comorbidities requiring chronic treatment were present in 27.5%, and comorbidities affecting self-sufficiency in 9.5%. Psychiatric comorbidity was present in 35.0%. Patients' priorities included discovery of the cause (89.1%), use of right drug (98.7%), use of a drug without chronic side effects (94.0%), and a life without restrictions (90.4%). Physicians' priorities included choice of right drug (83.5%) and use of drugs without chronic side effects (86.8%). Priorities varied with patients' age, sex, education, and occupation. Patient–doctor relationships were at least good in most cases. The information imparted was considered unsatisfactory by 21–44% of cases on seizure circumstances and complications, side effects of drugs, limitations of daily activities, and management of physiologic or pathologic conditions. Patients declared overall satisfaction, except for appointments (21.5%) and emergencies (30.8%). Conclusion: Patients and physicians' priorities in the mana

Published
2020

28. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

Author

Casadei-Gardini A., Dadduzio V., Rovesti G., Cabibbo G., Vukotic R., Rizzato M. D., Orsi G., Rossi M., Guarneri V., Lonardi S., D'agostino D., Celsa C., Andreone P., Zagonel V., Scartozzi M., Cascinu S., Cucchetti A., Casadei Gardini, A., Dadduzio, V., Rovesti, G., Cabibbo, G., Vukotic, R., Rizzato, M. D., Orsi, G., Rossi, M., Guarneri, V., Lonardi, S., D'Agostino, D., Celsa, C., Andreone, P., Zagonel, V., Scartozzi, M., Cascinu, S., Cucchetti, A., Casadei-Gardini A., Dadduzio V., Rovesti G., Cabibbo G., Vukotic R., Rizzato M.D., Orsi G., Rossi M., Guarneri V., Lonardi S., D'agostino D., Celsa C., Andreone P., Zagonel V., Scartozzi M., Cascinu S., and Cucchetti A.

Subjects
macro-vascular portal vein invasion, Male, Carcinoma, Hepatocellular, Antineoplastic Agents, extra hepatic disease and BCLC, survival, NLR, Antineoplastic Agent, Cohort Studies, alpha-fetoprotein, Humans, Lymphocyte Count, Survivors, prognostic factor, Aged, Liver Neoplasms, Middle Aged, Sorafenib, Progression-Free Survival, Italy, Liver Neoplasm, hepatitis C, Female, Cohort Studie, Carcinoma, Hepatocellular ...Liver Neoplasms, Human
Abstract

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional survival of patients without disease progression highlights that NLR and ECOG are the factors that most accurately predict the probability of long survival. The 3-year conditional survival of patients with disease progression showed a medium effect size for HCV status, alpha-fetoprotein and NLR at all time-points. Macro-vascular portal vein invasion, extra hepatic disease, and BCLC we have a large effect size at 6 months and a medium effect size at 12 and 24 months.Our findings support the use of baseline NLR for the identification of patients with a higher probability of long-survival. NLR should be used as a stratification factor in the forthcoming clinical trials on the drugs for the advanced HCC now in pipeline.

Published
2020

29. Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

Author

Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama, Annalisa, Tittarelli, Andrea, Barigelletti, Giulio, Botta, Laura, Gatta, Gemma, Tagliabue, Giovanna, Contiero, Paolo, Guzzinati, Stefano, Andreano, Anita, Manneschi, Gianfranco, Falcini, Fabio, Castaing, Marine, Filiberti, Rosa A, Gasparotti, Cinzia, Cirilli, Claudia, Mazzucco, Walter, Mangone, Lucia, Iacovacci, Silvia, Vitale, Maria F, Stracci, Fabrizio, Piffer, Silvano, Tumino, Rosario, Carone, Simona, Sampietro, Giuseppe, Melcarne, Anna, Ballotari, Paola, Boschetti, Lorenza, Pisani, Salvatore, Cavalieri D'Oro, Luca, Cuccaro, Francesco, D'Argenzio, Angelo, D'Orsi, Giancarlo, Fanetti, Anna C, Ardizzone, Antonino, Candela, Giuseppa, Savoia, Fabio, Pascucci, Cristiana, Castelli, Maurizio, Storchi, Cinzia, Bernasconi, Alice, Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama, Annalisa, Tittarelli, Andrea, Barigelletti, Giulio, Botta, Laura, Gatta, Gemma, Tagliabue, Giovanna, Contiero, Paolo, Guzzinati, Stefano, Andreano, Anita, Manneschi, Gianfranco, Falcini, Fabio, Castaing, Marine, Filiberti, Rosa A, Gasparotti, Cinzia, Cirilli, Claudia, Mazzucco, Walter, Mangone, Lucia, Iacovacci, Silvia, Vitale, Maria F, Stracci, Fabrizio, Piffer, Silvano, Tumino, Rosario, Carone, Simona, Sampietro, Giuseppe, Melcarne, Anna, Ballotari, Paola, Boschetti, Lorenza, Pisani, Salvatore, Cavalieri D'Oro, Luca, Cuccaro, Francesco, D'Argenzio, Angelo, D'Orsi, Giancarlo, Fanetti, Anna C, Ardizzone, Antonino, Candela, Giuseppa, Savoia, Fabio, Pascucci, Cristiana, Castelli, Maurizio, Storchi, Cinzia, and Bernasconi, Alice

Abstract

Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 AYA cancer survivors. The excess risk of developing any SMN (SIR, 1.6; 95% confidence interval, 1.5-1.7) was 60%. The excess risk of SMNs was significantly high for survivors of lymphomas; cancers of the breast, thyroid, female genital tract, digestive organs, gonads, and urinary tract; and melanomas. The cumulative incidence of all SMNs in AYA cancer survivors within 25 years of their first cancer diagnosis was approximately 10%. Subsequent tumors contributing to approximately 60% of all SMNs were breast cancer, colorectal cancer, corpus uteri cancer, and ovarian cancer in females and colorectal cancer, bladder cancer, prostate cancer, lung cancer, and lymphomas in males. Conclusions: These results highlight the need to personalize follow-up strategies for AYA cancer survivors.

Published
2022

30. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates

Author

Zorzi M., Zappa M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R. A., Vitarelli S., Russo A. G., Carrozzi G., D'Orsi G., Fusco M., Sini G. M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A. L., Cesaraccio R., Madeddu A., Fanetti A. C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Rugge M., Brustolin A., Castelli M., Zorzi M., Zappa M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R.A., Vitarelli S., Russo A.G., Carrozzi G., D'Orsi G., Fusco M., Sini G.M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Madeddu A., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Rugge M., Brustolin A., and Castelli M.

Subjects
Adenoma, Male, Colorectal cancer, colorectal cancer, Target population, colorectal cancer screening, NO, Screening programme, Single indicator, medicine, Humans, Mass Screening, National level, Early Detection of Cancer, Aged, Potential impact, business.industry, Incidence, Incidence (epidemiology), Gastroenterology, Colonoscopy, Colorectal Neoplasms, Female, Italy, Middle Aged, Occult Blood, Patient Compliance, Program Evaluation, medicine.disease, Colorectal cancer screening, business, Demography
Abstract

ObjectiveThe impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists’ sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.DesignWe defined the ‘rate of advanced adenoma on the target population’ (AA-TAP) as the rate of patients who received a diagnosis of advanced adenoma within a screening programme, divided by the programme target population. We computed the AA-TAP for the CRC Italian screening programmes (biennial faecal immunochemical test, target population 50–69 year olds) using the data of the Italian National Survey from 2003 to 2016, overall and by region, and assessed the association between AA-TAP and CRC incidence fitting a linear regression between the trend of regional CRC incidence rates in 50–74 year old subjects and the cumulative AA-TAP.ResultsIn 2016, the AA-TAP at a national level was 105×100 000, whereas significant differences were observed between the northern and central regions (respectively 126 and 149×100 000) and the South and Islands (36×100 000). The cumulative AA-TAP from 2004 to 2012 was significantly correlated with the difference between CRC incidence rates in 2013–2014 and those in 2003–2004 (p=0.009).ConclusionThe AA-TAP summarises into a single indicator the potential impact of a screening programme in reducing CRC incidence rates.

Published
2019
Full Text
View/download PDF

33. Individual Results from GCE Principal Investigators

Author

Arends, B. G., Kos, G. P. A., Möls, H. J., Berner, A., Solly, I., Kruisz, C., Bizjak, M., Berner, Ax., Grgic, I., Divjak, B., Hudnik, V., Kozak-Legiša, Š., Poje, M., Choularton, T., Gallagher, M. W., Bower, K. N., Colvile, R. N., Fuzzi, S., Facchini, M. C., Orsi, G., Laj, P., Gieray, R., Engelhardt, T., Wieser, P. A., Hallberg, A., Noone, K. J., Orgen, J. A., Hansson, H-C, Svenningsson, I. B., Swietlicki, E., Widensohler, A., Martinsson, B. G., Frank, G., Jaeschke, W., Georgii, H. W., Schell, D., Preiss, M., Maser, R., Wobrock, W., Levsen, K., Lüttke, J., Cederfelt, S. I., Hansson, H. C., Möller, D., Acker, K., Wieprecht, W., Auel, R., Winkler, P., Pahl, S., Borrell, Peter, editor, Borrell, Patricia M., editor, Cvitaš, Tomislav, editor, Kelly, Kerry, editor, Seiler, Wolfgang, editor, Fuzzi, Sandro, editor, and Wagenbach, Dietmar, editor

Published
1997
Full Text
View/download PDF

36. The Kleiner Feldberg Cloud Experiment 1990. An Overview

Author

Wobrock, W., Schell, D., Maser, R., Jaeschke, W., Georgii, H.-W., Wieprecht, W., Arends, B. G., Mols, J. J., Kos, G. P. A., Fuzzi, S., Facchini, M. C., Orsi, G., Berner, A., Solly, I., Kruisz, C., Svenningsson, I. B., Wiedensohler, A., Hansson, H.-C., Ogren, J. A., Noone, K. J., Hallberg, A., Pahl, S., Schneider, T., Winkler, P., Winiwarter, W., Colvile, R. N., Choularton, T. W., Flossmann, A. I., Borrmann, S., and Fuzzi, Sandro, editor

Published
1995
Full Text
View/download PDF

37. Computer Modelling of Clouds at Kleiner Feldberg

Author

Colvile, R. N., Sander, R., Choularton, T. W., Bower, K. N., Inglis, D. W. F., Wobrock, W., Schell, D., Svenningsson, I. B., Wiedensohler, A., Hansson, H.-C., Hallberg, A., Ogren, J. A., Noone, K. J., Facchini, M. C., Fuzzi, S., Orsi, G., Arends, B. G., Winiwarter, W., Schneider, T., Berner, A., and Fuzzi, Sandro, editor

Published
1995
Full Text
View/download PDF

40. Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3)

Author

Orsi G., Tovoli F., Dadduzio V., Vivaldi C., Brunetti O., Ielasi L., Conti F., Rovesti G., Gramantieri L., Rizzato M. D., Pecora I., Argentiero A., Teglia F., Lonardi S., Salani F., Granito A., Zagonel V., Marisi G., Cabibbo G., Foschi F. G., Benevento F., Cucchetti A., Piscaglia F., Cascinu S., Scartozzi M., Casadei-Gardini A., Orsi G., Tovoli F., Dadduzio V., Vivaldi C., Brunetti O., Ielasi L., Conti F., Rovesti G., Gramantieri L., Rizzato M.D., Pecora I., Argentiero A., Teglia F., Lonardi S., Salani F., Granito A., Zagonel V., Marisi G., Cabibbo G., Foschi F.G., Benevento F., Cucchetti A., Piscaglia F., Cascinu S., Scartozzi M., and Casadei-Gardini A.

Subjects
not applicable
Abstract

An Online First version of this article was made available online at https://link.springer.com/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were subsequently identified in the article, and the following corrections should be noted.

Published
2020

41. Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults

Author

Zorzi M., Cavestro G. M., Guzzinati S., Dal Maso L., Rugge M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R. A., Vitarelli S., Russo A. G., Carrozzi G., D'Orsi G., Fusco M., Sini G. M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A. L., Cesaraccio R., Madeddu A., Fanetti A. C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Tolin M., Brustolin A., Castelli M., Zorzi M., Cavestro G.M., Guzzinati S., Dal Maso L., Rugge M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R.A., Vitarelli S., Russo A.G., Carrozzi G., D'Orsi G., Fusco M., Sini G.M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Madeddu A., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Tolin M., Brustolin A., Castelli M., Zorzi, M., Cavestro, G. M., Guzzinati, S., Dal Maso, L., and Rugge, M

Subjects
0301 basic medicine, Colon, Population, Socio-culturale, colorectal cancer, colorectal cancer screening, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Epidemiology of cancer, Medicine, Humans, Risk factor, education, education.field_of_study, cancer epidemiology, Colorectal cancer, colorectal cancer screening, business.industry, Incidence (epidemiology), Mortality rate, screening, Incidence, Gastroenterology, Cancer, medicine.disease, Obesity, Annual Percent Change, Europe, 030104 developmental biology, Italy, 030211 gastroenterology & hepatology, epidemiology, business, Colorectal Neoplasms, Demography, cancer epidemiology, SEER Program
Abstract

Objective The incidence of colorectal cancer (CRC) declines among subjects aged 50 years and above. An opposite trend appears among younger adults. In Europe, data on CRC incidence among younger adults are lacking. We therefore aimed to analyse European trends in CRC incidence and mortality in subjects younger than 50 years. Design Data on age-related CRC incidence and mortality between 1990 and 2016 were retrieved from national and regional cancer registries. Trends were analysed by Joinpoint regression and expressed as annual percent change. Results We retrieved data on 143.7 million people aged 20–49 years from 20 European countries. Of them, 187 918 (0.13%) were diagnosed with CRC. On average, CRC incidence increased with 7.9% per year among subjects aged 20–29 years from 2004 to 2016. The increase in the age group of 30–39 years was 4.9% per year from 2005 to 2016, the increase in the age group of 40–49 years was 1.6% per year from 2004 to 2016. This increase started earliest in subjects aged 20–29 years, and 10–20 years later in those aged 30–39 and 40–49 years. This is consistent with an age-cohort phenomenon. Although in most European countries the CRC incidence had risen, some heterogeneity was found between countries. CRC mortality did not significantly change among the youngest adults, but decreased with 1.1%per year between 1990 and 2016 and 2.4% per year between 1990 and 2009 among those aged 30–39 years and 40–49 years, respectively. Conclusion CRC incidence rises among young adults in Europe. The cause for this trend needs to be elucidated. Clinicians should be aware of this trend. If the trend continues, screening guidelines may need to be reconsidered.

Published
2020

50. 1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)

Author

Orsi, G., primary, Milella, M., additional, Nappo, F., additional, Di Marco, M., additional, Niger, M., additional, Bozzarelli, S., additional, Rodriquenz, M.G., additional, Noventa, S., additional, Giordano, G., additional, Rapposelli, I.G., additional, Bernardini, I., additional, Vasile, E., additional, Macchini, M., additional, Peretti, U., additional, Valente, M.M., additional, Paratore, C., additional, Spallanzani, A., additional, Scartozzi, M., additional, Cascinu, S., additional, and Reni, M., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results